Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026

Rhea-AI Summary

Revolution Medicines (Nasdaq: RVMD) will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026 after market close. A senior management webcast will begin at 4:30 p.m. ET (1:30 p.m. PT) to discuss results and corporate progress. A replay will be available on the company website for at least 14 days.

News Market Reaction – RVMD

-0.82%

1 alert

-0.82% News Effect

On the day this news was published, RVMD declined 0.82%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings report date: February 25, 2026 Earnings call time ET: 4:30 p.m. ET Earnings call time PT: 1:30 p.m. PT +1 more

4 metrics

Earnings report date February 25, 2026 Fourth quarter and full year 2025 results release after market close

Earnings call time ET 4:30 p.m. ET Start time for webcast to discuss Q4 and full-year results

Earnings call time PT 1:30 p.m. PT Pacific Time for the same webcast event

Webcast replay period 14 days Replay available on company website after the live webcast

Market Reality Check

Price: $101.83 Vol: Volume 1,482,309 is below...

low vol

$101.83 Last Close

Volume Volume 1,482,309 is below the 2,890,415 share 20-day average. low

Technical Trading at $100.61, well above 200-day MA of $57.62 and 19.18% below the $124.49 52-week high, up 244.91% from the $29.17 52-week low.

Peers on Argus

RVMD is up 4.46% with below-average volume, while key biotech peers show smaller...

RVMD is up 4.46% with below-average volume, while key biotech peers show smaller mixed gains (e.g., MDGL +5.4%, MRNA +3.9%, ROIV +2.85%), suggesting stock-specific strength rather than a synchronized sector move.

Historical Context

5 past events · Latest: Feb 04 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 04	Conference participation	Neutral	-0.4%	Announcement of participation in Guggenheim biotech summit with webcast access.
Jan 29	Clinical trial start	Positive	+0.9%	First patient dosed in first-in-human trial for RMC-5127 RAS(ON) G12V inhibitor.
Jan 08	Regulatory designation	Positive	+4.6%	FDA Breakthrough Therapy Designation granted for zoldonrasib in NSCLC.
Jan 05	Conference presentation	Neutral	+1.9%	J.P. Morgan Healthcare Conference presentation with live and replay webcast.
Dec 18	Phase 3 trial update	Positive	-1.0%	First patient randomized in global Phase 3 RASolute 304 trial of daraxonrasib.

Pattern Detected

Recent company-specific news, especially regulatory designations and trial initiations, often coincided with positive price moves, while some neutral or incremental updates saw flat-to-slightly negative reactions.

Recent Company History

Over the last few months, RVMD has reported several clinical and regulatory milestones. On Dec 18, 2025, the first patient was randomized in the Phase 3 RASolute 304 trial of daraxonrasib, followed by additional clinical progress with first dosing of RMC-5127 on Jan 29, 2026. A key highlight was the FDA Breakthrough Therapy Designation for zoldonrasib on Jan 8, 2026, which saw a positive price reaction. Conference and investor event announcements around early January and February produced relatively modest share moves. Today’s earnings date notice fits into this pattern of procedural, investor-focused communications.

Market Pulse Summary

This announcement sets the schedule for RVMD’s fourth quarter and full year 2025 financial results o...

Analysis

This announcement sets the schedule for RVMD’s fourth quarter and full year 2025 financial results on February 25, 2026, with a webcast at 4:30 p.m. ET and replay access for at least 14 days. In recent months, the company has highlighted Phase 3 trial progress and an FDA Breakthrough Therapy Designation, alongside conference appearances. Investors may focus on how upcoming financial details align with this expanding clinical footprint and prior regulatory achievements.

AI-generated analysis. Not financial advice.

REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, February 25, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress.

To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.

About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.

Revolution Medicines Media & Investor Contact:
media@revmed.com 
investors@revmed.com 

FAQ

When will Revolution Medicines (RVMD) release Q4 and full year 2025 results?

Revolution Medicines will release Q4 and full year 2025 results on February 25, 2026 after market close. According to the company, the announcement will be followed by a 4:30 p.m. ET webcast with senior management to discuss financials and corporate progress.

How can investors join the Revolution Medicines (RVMD) earnings webcast on February 25, 2026?

Investors can join the live webcast via the company investor website at the specified events page. According to the company, the webcast begins at 4:30 p.m. ET (1:30 p.m. PT) and will feature senior management discussing the quarter and full year results.

Will the Revolution Medicines (RVMD) earnings webcast be available after the live event?

Yes, a replay of the webcast will be available on the company website for at least 14 days after the live event. According to the company, the archived webcast can be accessed via its events and presentations page for on-demand listening.

What will Revolution Medicines (RVMD) management cover during the February 25, 2026 webcast?

Management will discuss fourth quarter and full year 2025 financial results and provide a corporate progress update. According to the company, senior management will address financial metrics and recent program developments during the webcast session.

Where can I find the Revolution Medicines (RVMD) webcast link and replay for the February 25, 2026 results?

The webcast link and replay will be posted on the company's investor events and presentations page. According to the company, both the live webcast and archived replay will be accessible via https://ir.revmed.com/events-and-presentations.